STOCK TITAN

MeiraGTx (MGTX) Form 144: $379k share sale slated for July 2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 filing overview for MeiraGTx Holdings plc (MGTX)

The notice discloses a proposed sale of 47,500 ordinary shares through Merrill Lynch, 200 Park Avenue, New York, NY 10166. The transaction is scheduled for approximately 08 July 2025 on the NASDAQ exchange.

  • Aggregate market value: $378,575
  • Total shares outstanding: 80,365,359
  • Percentage of float affected: ≈0.06%

The shares were originally acquired via incentive compensation stock grants on 02 March 2018 (35,625 shares) and 07 June 2018 (11,875 shares). The filer reports no other share sales within the past three months.

Because the sale represents a small fraction of outstanding stock and stems from equity compensation, the filing is generally considered routine. Investors often monitor Form 144s to gauge insider sentiment; however, the scale here is unlikely to materially impact market dynamics.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider Form 144; 47.5k shares (<0.1% float) slated for 8 Jul 2025; negligible market impact expected.

The proposed sale involves fewer than fifty-thousand shares valued at roughly $379k, against an 80 million-share base. Such transactions are common for executives monetising compensation grants. No pattern of recent selling is disclosed, and the filing contains no price-sensitive operational details. Given the minimal dilution and transparent disclosure, I classify the event as neutral for valuation and liquidity.

TL;DR: Insider liquidity event via Rule 144; governance risk low, signal impact limited.

The transaction follows Rule 144 procedures, indicating compliance with insider-trading safeguards. Absence of a 10b5-1 adoption date in the form means the filer may rely on a standing plan or non-plan discretionary sale, but the representation affirms no undisclosed adverse information. Scale is modest and not concentrated, so governance concerns are minimal.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many MGTX shares are being sold under this Form 144?

47,500 ordinary shares are proposed for sale.

What is the aggregate market value of the proposed sale?

The filing lists an aggregate value of $378,575.

When is the approximate sale date for the MGTX shares?

The shares are expected to be sold on or about 07/08/2025.

How were the shares originally acquired?

They were obtained via incentive compensation stock grants on 03/02/2018 and 06/07/2018.

What percentage of MeiraGTx's total shares does this sale represent?

Roughly 0.06% of the 80,365,359 shares outstanding.

Were any other MGTX shares sold by the filer in the last three months?

The form states "Nothing to Report" for prior three-month sales.
Meiragtx Holdings Plc

NASDAQ:MGTX

MGTX Rankings

MGTX Latest News

MGTX Latest SEC Filings

MGTX Stock Data

596.44M
53.46M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
NEW YORK